| | Tuesday, October 15, 2019 | How to Play This Year's Most Catastrophic IPO Yet | | Dear Startup Investor,
It's been a rough year for tech IPOs.
Some of the most highly-anticipated debuts - Uber, Lyft, Slack, and Peloton, to name a few - have seen some of the most precipitous first-year drops the market has seen in decades.
But SmileDirectClub (NASDAQ:SDC) takes the cake. This startup, founded in 2014, is a direct-to-consumer (D2C) seller of clear orthodontic aligners that cost 60% less than braces.
Despite promising financials and a growing user base, SDC stock has suffered considerably, dropping nearly 60% in just over a month. That's a crushing blow for anyone who bought SDC stock at the IPO - but little more than a chilly breeze for its angel investors.
While we can only guess at the details of SDC's earliest funding rounds, it's pretty typical for a seed-stage company to land at a valuation around $10 million. That means, even with its latest slide, SmileDirectClub has probably grown by about 59,900% since its earliest funding rounds.
With the economy growing more volatile, and the possibility of a recession looming, savvy investors are likely to shy away from trading stocks. Why spend your time watching your portfolio eke out a few points here and there when you could wait a little longer and potentially hit the jackpot?
For example... Right now I'm looking at a company that's poised to completely revolutionize the "wearable tech" market.
Plenty of public companies make wearables now - Apple Watches, Fitbits, and so on - but this tiny company is developing a completely new type of tech that could change everything about the way we interact with our world.
Experts project that by 2023, consumers will buy 200 million wearable devices annually. That means if this startup harnesses even just a tiny piece of the market, it'll have the potential to reach unicorn status in just a few years' time.
Personally, I think they have a pretty good shot - but they won't be accepting investors for much longer. Just click here to learn more.
Until next time, Neil | | Trending | | | | Stay Connected | | Please do not reply to this email. It was sent from an unmonitored mailbox.
You are receiving this e-mail at phanphuongthanh89.822152@blogger.com, as part of your subscription to The Startup Investor. To remove your email from this list: Unsubscribe here. To cancel, or for any other questions or requests, please contact our Customer Service team: Online Phone: 866-310-1498 (North America) 410-501-5876 (International) Mail: The Startup Investor| Attn: Member Services | 1125 N Charles Street | Baltimore, MD 21201 Fax: 410-713-4352 Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2019 Angels & Entrepreneurs, LLC. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Angels & Entrepreneurs, LLC. 1125 N Charles Street, Baltimore MD 21201. Website | Privacy Policy | Terms & Conditions | |
No comments:
Post a Comment